GLP-1 Drugs: Boost for Type 2 Diabetes and PAD?
New research indicates that GLP-1 receptor agonist medications significantly reduce mortality, amputations, and hospitalizations in patients with Type 2 diabetes and peripheral artery disease. The study suggests these drugs outperform metformin in managing cardiovascular risks for high-risk patients.
Why it matters
These findings could shift clinical treatment standards for patients suffering from the intersection of diabetes and severe circulatory issues.
DALLAS, July 1, 2026 - GLP-1 receptor agonists (GLP-1 RA) medications were shown to reduce the number of deaths, amputations and hospitalizations among people with Type 2 diabetes who also had narrowed leg arteries associated with PAD (peripheral artery disease) , according to new, independent research published today in the Journal of the American Heart Association , an open-access, peer-reviewed journal of the American Heart Association.
The article summarizes peer-reviewed medical research findings objectively.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in